BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 23107469)

  • 1. Analysis of the MTHFR (methylenetetrahydrofolate reductase) 677 C>T and 1298 A>C polymorphisms in BCR-ABL-negative myeloproliferative neoplasms.
    Trifa AP; Cucuianu A; Popp RA; Costache RM; Coadă CA; Sarca AD; Urian LG; Dima D; Petrov L; Farcaş MF; Militaru MS; Pop IV
    Int J Lab Hematol; 2013 Feb; 35(1):e9-12. PubMed ID: 23107469
    [No Abstract]   [Full Text] [Related]  

  • 2. Oxidative stress is increased in primary and post-polycythemia vera myelofibrosis.
    Vener C; Novembrino C; Catena FB; Fracchiolla NS; Gianelli U; Savi F; Radaelli F; Fermo E; Cortelezzi A; Lonati S; Menegatti M; Deliliers GL
    Exp Hematol; 2010 Nov; 38(11):1058-65. PubMed ID: 20655352
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The relationship between factor V Leiden, prothrombin G20210A, and MTHFR mutations and the first major thrombotic episode in polycythemia vera and essential thrombocythemia.
    Trifa AP; Cucuianu A; Popp RA; Coadă CA; Costache RM; Militaru MS; Vesa ŞC; Pop IV
    Ann Hematol; 2014 Feb; 93(2):203-9. PubMed ID: 23828072
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evaluation of the association between the JAK2 46/1 haplotype and myeloproliferative neoplasm in a Korean population.
    Park SG; Ha JS
    Int J Lab Hematol; 2015 Aug; 37(4):e91-5. PubMed ID: 25630751
    [No Abstract]   [Full Text] [Related]  

  • 5. MicroRNA expression and JAK2 allele burden in bone marrow trephine biopsies of polycythemia vera, essential thrombocythemia and early primary myelofibrosis.
    Gebauer N; Bernard V; Gebauer W; Feller AC; Merz H
    Acta Haematol; 2013; 129(4):251-6. PubMed ID: 23343777
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Management strategy for BCR-ABL negative myeloproliferative neoplasms].
    Gotoh A; Komatsu N
    Rinsho Ketsueki; 2014 Jan; 55(1):56-65. PubMed ID: 24492037
    [No Abstract]   [Full Text] [Related]  

  • 7. The diagnosis and management of polycythemia vera, essential thrombocythemia, and primary myelofibrosis in the JAK2 V617F era.
    Zhan H; Spivak JL
    Clin Adv Hematol Oncol; 2009 May; 7(5):334-42. PubMed ID: 19521323
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Long term follow up of 93 families with myeloproliferative neoplasms: life expectancy and implications of JAK2V617F in the occurrence of complications.
    Malak S; Labopin M; Saint-Martin C; Bellanne-Chantelot C; Najman A;
    Blood Cells Mol Dis; 2012 Oct 15-Dec 15; 49(3-4):170-6. PubMed ID: 22818858
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The influence of novel transcriptional regulatory element in intron 14 on the expression of Janus kinase 2 gene in myeloproliferative neoplasms.
    Spasovski V; Tosic N; Nikcevic G; Stojiljkovic M; Zukic B; Radmilovic M; Karan-Djurasevic T; Srzentic S; Colovic M; Pavlovic S
    J Appl Genet; 2013 Feb; 54(1):21-6. PubMed ID: 23188718
    [TBL] [Abstract][Full Text] [Related]  

  • 10. ASXL1 mutations in primary and secondary myelofibrosis.
    Ricci C; Spinelli O; Salmoiraghi S; Finazzi G; Carobbio A; Rambaldi A
    Br J Haematol; 2012 Feb; 156(3):404-7. PubMed ID: 21923651
    [No Abstract]   [Full Text] [Related]  

  • 11. JAK2 GGCC haplotype in MPL mutated myeloproliferative neoplasms.
    Pietra D; Casetti I; Da Vià MC; Elena C; Milanesi C; Rumi E
    Am J Hematol; 2012 Jul; 87(7):746-7. PubMed ID: 22565617
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The JAK2 V617F allele burden in essential thrombocythemia, polycythemia vera and primary myelofibrosis--impact on disease phenotype.
    Larsen TS; Pallisgaard N; Møller MB; Hasselbalch HC
    Eur J Haematol; 2007 Dec; 79(6):508-15. PubMed ID: 17961178
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pathogenetic insight and prognostic information from standard and molecular cytogenetic studies in the BCR-ABL-negative myeloproliferative neoplasms (MPNs).
    Reilly JT
    Leukemia; 2008 Oct; 22(10):1818-27. PubMed ID: 18754027
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Different involvement of the megakaryocytic lineage by the JAK2 V617F mutation in Polycythemia vera, essential thrombocythemia and chronic idiopathic myelofibrosis.
    Hussein K; Brakensiek K; Buesche G; Buhr T; Wiese B; Kreipe H; Bock O
    Ann Hematol; 2007 Apr; 86(4):245-53. PubMed ID: 17262192
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The JAK2V617F allele burden and STAT3- and STAT5 phosphorylation in myeloproliferative neoplasms: early prefibrotic myelofibrosis compared with essential thrombocythemia, polycythemia vera and myelofibrosis.
    Risum M; Madelung A; Bondo H; Bzorek M; Kristensen MH; Stamp IM; Hasselbalch HC
    APMIS; 2011 Aug; 119(8):498-504. PubMed ID: 21749449
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Gene expression profiling with principal component analysis depicts the biological continuum from essential thrombocythemia over polycythemia vera to myelofibrosis.
    Skov V; Thomassen M; Riley CH; Jensen MK; Bjerrum OW; Kruse TA; Hasselbalch HC; Larsen TS
    Exp Hematol; 2012 Sep; 40(9):771-780.e19. PubMed ID: 22659388
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Novel method in diagnosis of chronic myeloproliferative disorders--detection of JAK2 mutation].
    Rajnai H; Bödör C; Reiniger L; Timár B; Csernus B; Szepesi A; Csomor J; Matolcsy A
    Orv Hetil; 2006 Nov; 147(45):2175-9. PubMed ID: 17402211
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A higher JAK2 V617F-mutated clone is observed in platelets than in granulocytes from essential thrombocythemia patients, but not in patients with polycythemia vera and primary myelofibrosis.
    Bellosillo B; Martínez-Avilés L; Gimeno E; Florensa L; Longarón R; Navarro G; Salar A; Espinet B; Solé F; Serrano S; Besses C
    Leukemia; 2007 Jun; 21(6):1331-2. PubMed ID: 17361221
    [No Abstract]   [Full Text] [Related]  

  • 19. GATA1 is overexpressed in patients with essential thrombocythemia and polycythemia vera but not in patients with primary myelofibrosis or chronic myelogenous leukemia.
    Rinaldi CR; Martinelli V; Rinaldi P; Ciancia R; del Vecchio L
    Leuk Lymphoma; 2008 Jul; 49(7):1416-9. PubMed ID: 18452096
    [No Abstract]   [Full Text] [Related]  

  • 20. Myeloproliferative neoplasms 2012: the John M. Bennett 80th birthday anniversary lecture.
    Tefferi A
    Leuk Res; 2012 Dec; 36(12):1481-9. PubMed ID: 22917768
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.